🇺🇸 Lopinavir/ritonavir (Kaletra) in United States

35 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Maternal Drugs Affecting Foetus — 13 reports (37.14%)
  2. Congenital Anomaly — 4 reports (11.43%)
  3. Abortion Spontaneous — 3 reports (8.57%)
  4. Exposure During Pregnancy — 3 reports (8.57%)
  5. Volvulus — 3 reports (8.57%)
  6. Abortion Induced — 2 reports (5.71%)
  7. Dialysis — 2 reports (5.71%)
  8. Maternal Exposure During Pregnancy — 2 reports (5.71%)
  9. Trisomy 21 — 2 reports (5.71%)
  10. Abnormal Dreams — 1 report (2.86%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Lopinavir/ritonavir (Kaletra) approved in United States?

Lopinavir/ritonavir (Kaletra) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Lopinavir/ritonavir (Kaletra) in United States?

Abbott is the originator. The local marketing authorisation holder may differ — check the official source linked above.